Hannover (ots) –
- Ex-German Bank chief Juergen Fitschen occurs as a new Investor in Syntellix supervisory board a - Also, financial market strategist Rolf Elgeti now Syntellix shareholder - International IPO planned - Market entry into Indonesia as the next milestone
Former EnBW- and Sartorius CEO Prof. Dr. Utz Claassen takes over as the founder and main shareholder with immediate effect as Chairman of Syntellix AG in Hannover. That gave Claassen, who has held since the founding of the company whose board chairmanship, announced at the 10-year anniversary celebration of the anniversary of the biomedical high-tech company in Hannover-Herrenhausen. Supervisory Board colleagues and investors had asked him for some time to this step, so Claassen, the unique potential of the innovative start-up company in the best possible exploit, to further accelerate its strategic and operational performance and to allow an international IPO. In addition to the current exchange's preferred location Singapore, were initiated at the appropriate preparations already, would this alternative Shanghai and the US NASDAQ stock exchange in question. The most successful IPOs of technology-oriented start-ups in recent years would be almost universally characterized, that the founder also acts as CEO personally.
The current CEO of Syntellix AG, Thomas Mayer, will remain on the board of the company and concentrate fully on the CFO as finance further expansion and the financial side preparation for the IPO.
As “Bang for the company” Claassen announced the already completed entry of ex-German Bank chief Juergen Fitschen as other key investor, the are elected at the next general meeting in the company's supervisory board and this then together with Claassen wife Annette Claassen, the initially assumed the chairmanship of the committee, should lead.
Claassen evaluated Fitschens commitment to Syntellix as “absolute godsend and the best, what can a high-potential companies happen at all”. Fitschen as an internationally highly regarded top bankers was one of the bestvernetzten, most competent and most decent people, which he had ever met, and could contribute significantly, to lift the company also in the global context again to a whole new level. Rolf Elgeti, which was named by industry publication Thomson Extel Survey twice for best equity strategists of Europe and called one of the most brilliant financial analysts the banking world, has invested over his holding company Hevella Capital in Syntellix shares. With its unique experience in London's financial world, among others at UBS, Commerzbank and ABN Amro, it can just as Fitschen support the desired international IPO Syntellix significantly.
Claassen, still the majority shareholder, described the successful broadening of the shareholder as “the greatest possible compliment and best birthday present” for Syntellix AG. After many thousands of patients have already been successfully treated with the truly unique implants Syntellix AG, would it have to focus on, to let millions of patients benefit from the Syntellix products, bring significant benefits to patients, ranging from the elimination of a sequence operation for implant removal, and thus a reduced risk of infection to an accelerated and improved healing and a correspondingly high patient satisfaction. With Fitschen and Elgeti as global financial strategists on board this mission should now be implemented quickly. The next operational milestone of globalization efforts of the Hanoverian company Claassen announced its market entry in Indonesia, the fourth most populous country in the world, for the next quarter. The Syntellix AG is the world leader in the field of bio-absorbable metallic orthopedic implants and has already received numerous important awards and prizes, including the Innovation Award of German Industry, the future price of the German healthcare industry 2016, dem German Medical Award 2017, dem STEP Award 2017 as well as “Innovator of the Year 2017”. Claassen personally received in 2016 from the hands of EU Commissioner Günther Oettinger, not least in the light of its commitment to the Syntellix AG the award for “Innovativster entrepreneurs internationally in 2016”.
Syntellix AG Aegidientorplatz 2a 30159 Hanover Germany
T +49 511 270 413 50 F +49 511 270 413 79
Board Prof. Dr. rer. pol. Utz Claassen Chairman / CEO Dipl.-Kfm. Thomas Mayer CFO Prof. Dr. with. Martin Kirschner CTO
Supervisory Board Chairman Annette Claassen
Company headquarters Hanover District Court Hannover HRB 202618
Caroline Meyer-Maltseva PR
CATO firm for
Prof. Dr. Klaus Kocks
Original content of: Syntellix AG, news transmitted by currently